Chairman of the Board
Ken Narducy is also currently President and a Director of St Charles Pharmaceuticals, a private CNS and Neurodegenerative Disease pharmaceutical company.
Prior to this time, he was employed as VP and General Manager, Centaur Pharmaceuticals Inc, a CNS Pharmaceutical Company; Executive VP and President/Executive Vice President at Oculex Pharmaceuticals, an Opthalmic drug company; Vice President of Research and Development at CooperVision Ophthalmic Products, a major contact lens and solutions company; Director of Research and Development at Wesley-Jessen, a leading manufacturer of contact lenses; and Manager of Research and Development at Abbott Laboratories, a multi-billion dollar healthcare company.
Dr. Narducyhas many years of drug development experience and is a highly regarded and effective senior manager, pharmaceutical executive and physical organic chemist. Dr. Narducy has been a pharmaceutical expert and executive for many years. Previously, he has been a key manager and scientist at nine companies involved in the development and commercialization of therapeutic drugs and ophthalmic products.
The value of Dr. Narducy's previous business transactions exceeds $1B. He is also a STTR/SBIR Grants strategist and business officer and has been awarded approximately $2.9M in SBIR/STTR Phase I and Phase II grants over the last few years.
Dr. Narducy holds a Ph.D. in Physical Organic Chemistry from Ohio State University and an MBA in Marketing & Finance from the University of Chicago.
